Literature DB >> 26503377

VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy.

Hilary Highfield Nickols1, Joannes P Yuh2, Karen J Gregory2, Ryan D Morrison2, Brittney S Bates2, Shaun R Stauffer2, Kyle A Emmitte2, Michael Bubser2, Weimin Peng2, Michael T Nedelcovych2, Analisa Thompson2, Xiaohui Lv2, Zixiu Xiang2, J Scott Daniels2, Colleen M Niswender2, Craig W Lindsley2, Carrie K Jones2, P Jeffrey Conn2.   

Abstract

Negative allosteric modulators (NAMs) of metabotropic glutamate receptor subtype 5 (mGlu5) have potential applications in the treatment of fragile X syndrome, levodopa-induced dyskinesia in Parkinson disease, Alzheimer disease, addiction, and anxiety; however, clinical and preclinical studies raise concerns that complete blockade of mGlu5 and inverse agonist activity of current mGlu5 NAMs contribute to adverse effects that limit the therapeutic use of these compounds. We report the discovery and characterization of a novel mGlu5 NAM, N,N-diethyl-5-((3-fluorophenyl)ethynyl)picolinamide (VU0477573) that binds to the same allosteric site as the prototypical mGlu5 NAM MPEP but displays weak negative cooperativity. Because of this weak cooperativity, VU0477573 acts as a "partial NAM" so that full occupancy of the MPEP site does not completely inhibit maximal effects of mGlu5 agonists on intracellular calcium mobilization, inositol phosphate (IP) accumulation, or inhibition of synaptic transmission at the hippocampal Schaffer collateral-CA1 synapse. Unlike previous mGlu5 NAMs, VU0477573 displays no inverse agonist activity assessed using measures of effects on basal [(3)H]inositol phosphate (IP) accumulation. VU0477573 acts as a full NAM when measuring effects on mGlu5-mediated extracellular signal-related kinases 1/2 phosphorylation, which may indicate functional bias. VU0477573 exhibits an excellent pharmacokinetic profile and good brain penetration in rodents and provides dose-dependent full mGlu5 occupancy in the central nervous system (CNS) with systemic administration. Interestingly, VU0477573 shows robust efficacy, comparable to the mGlu5 NAM MTEP, in models of anxiolytic activity at doses that provide full CNS occupancy of mGlu5 and demonstrate an excellent CNS occupancy-efficacy relationship. VU0477573 provides an exciting new tool to investigate the efficacy of partial NAMs in animal models.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26503377      PMCID: PMC4702078          DOI: 10.1124/jpet.115.226597

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  98 in total

Review 1.  Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives.

Authors:  Fabrizio Gasparini; Rainer Kuhn; Jean-Philippe Pin
Journal:  Curr Opin Pharmacol       Date:  2002-02       Impact factor: 5.547

2.  Chemical induction of mGluR5- and protein synthesis--dependent long-term depression in hippocampal area CA1.

Authors:  K M Huber; J C Roder; M F Bear
Journal:  J Neurophysiol       Date:  2001-07       Impact factor: 2.714

Review 3.  Modulation of the basal ganglia by metabotropic glutamate receptors: potential for novel therapeutics.

Authors:  Michael J Marino; P Jeffrey Conn; Jeffrey P Conn
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2002-06

4.  5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity.

Authors:  Jeffrey R Roppe; Bowei Wang; Dehua Huang; Lida Tehrani; Theodore Kamenecka; Edwin J Schweiger; Jeffery J Anderson; Jesse Brodkin; Xiaohui Jiang; Merryl Cramer; Janice Chung; Grace Reyes-Manalo; Benito Munoz; Nicholas D P Cosford
Journal:  Bioorg Med Chem Lett       Date:  2004-08-02       Impact factor: 2.823

5.  3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure in rats.

Authors:  Andrew S Felts; Stacey R Lindsley; Jeffrey P Lamb; Alice L Rodriguez; Usha N Menon; Satyawan Jadhav; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley; Kyle A Emmitte
Journal:  Bioorg Med Chem Lett       Date:  2010-06-15       Impact factor: 2.823

6.  Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study.

Authors:  J C Pecknold; D J McClure; L Appeltauer; L Wrzesinski; T Allan
Journal:  J Clin Psychopharmacol       Date:  1982-04       Impact factor: 3.153

Review 7.  Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.

Authors:  Chad J Swanson; Mark Bures; Michael P Johnson; Anni-Maija Linden; James A Monn; Darryle D Schoepp
Journal:  Nat Rev Drug Discov       Date:  2005-02       Impact factor: 84.694

8.  Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist.

Authors:  Jörgen Jensen; Anders Lehmann; Anna Uvebrant; Anita Carlsson; Gunilla Jerndal; Karolina Nilsson; Claudine Frisby; L Ashley Blackshaw; Jan P Mattsson
Journal:  Eur J Pharmacol       Date:  2005-09-05       Impact factor: 4.432

9.  Differential regulation of metabotropic glutamate receptor 5-mediated phosphoinositide hydrolysis and extracellular signal-regulated kinase responses by protein kinase C in cultured astrocytes.

Authors:  Richard D Peavy; Scott D Sorensen; P Jeffrey Conn
Journal:  J Neurochem       Date:  2002-10       Impact factor: 5.372

10.  Metabotropic glutamate receptor 5 negative modulation in phase I clinical trial: potential impact of circadian rhythm on the neuropsychiatric adverse reactions-do hallucinations matter?

Authors:  Khalid Abou Farha; Richard Bruggeman; Corine Baljé-Volkers
Journal:  ISRN Psychiatry       Date:  2014-03-04
View more
  12 in total

Review 1.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

2.  Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology.

Authors:  Kathy Sengmany; Shane D Hellyer; Sabine Albold; Taide Wang; P Jeffrey Conn; Lauren T May; Arthur Christopoulos; Katie Leach; Karen J Gregory
Journal:  Neuropharmacology       Date:  2019-02-11       Impact factor: 5.250

Review 3.  Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.

Authors:  Daniel J Foster; P Jeffrey Conn
Journal:  Neuron       Date:  2017-05-03       Impact factor: 17.173

Review 4.  Metabotropic glutamate receptor 5 as a potential target for smoking cessation.

Authors:  Cristiano Chiamulera; Claudio Marcello Marzo; David J K Balfour
Journal:  Psychopharmacology (Berl)       Date:  2016-11-16       Impact factor: 4.530

Review 5.  The neurobiological basis for novel experimental therapeutics in dystonia.

Authors:  Anthony M Downs; Kaitlyn M Roman; Simone A Campbell; Antonio Pisani; Ellen J Hess; Paola Bonsi
Journal:  Neurobiol Dis       Date:  2019-07-04       Impact factor: 5.996

6.  Clickable Photoaffinity Ligands for Metabotropic Glutamate Receptor 5 Based on Select Acetylenic Negative Allosteric Modulators.

Authors:  Karen J Gregory; Ranganadh Velagaleti; David M Thal; Ryan M Brady; Arthur Christopoulos; P Jeffrey Conn; David J Lapinsky
Journal:  ACS Chem Biol       Date:  2016-05-04       Impact factor: 5.100

7.  Analysis of positive and negative allosteric modulation in metabotropic glutamate receptors 4 and 5 with a dual ligand.

Authors:  James A R Dalton; Jean-Philippe Pin; Jesús Giraldo
Journal:  Sci Rep       Date:  2017-07-10       Impact factor: 4.379

8.  Metabotropic glutamate receptor 5 binding in male patients with alcohol use disorder.

Authors:  Funda Akkus; Yoan Mihov; Valerie Treyer; Simon M Ametamey; Anass Johayem; Smeralda Senn; Susanne Rösner; Alfred Buck; Gregor Hasler
Journal:  Transl Psychiatry       Date:  2018-01-10       Impact factor: 6.222

9.  In Vitro Functional Characterization of GET73 as Possible Negative Allosteric Modulator of Metabotropic Glutamate Receptor 5.

Authors:  Sarah Beggiato; Andrea C Borelli; Maria C Tomasini; M Paola Castelli; Nicholas Pintori; Roberto Cacciaglia; Antonella Loche; Luca Ferraro
Journal:  Front Pharmacol       Date:  2018-04-05       Impact factor: 5.810

Review 10.  Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.

Authors:  Shalini Dogra; P Jeffrey Conn
Journal:  Neuropharmacology       Date:  2021-06-25       Impact factor: 5.273

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.